BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 7, 2025
See today's BioWorld
Home
» Vernalis embracing specialty pharma evolution with Tuzistra nod in U.S.
To read the full story,
subscribe
or
sign in
.
Vernalis embracing specialty pharma evolution with Tuzistra nod in U.S.
May 4, 2015
By
Nuala Moran
No Comments
LONDON – The commercial prospects of Vernalis plc are about to be transformed following FDA approval of its lead prescription cough-cold product, Tuzistra.
BioWorld